Sign inJoin waitlistJoin the waitlist

KR

Kerry Rogers

Translational Research Advocate · Ohio State University Hospital

Credentials: · · · · · ·

History

Ohio State University Hospital
Present

Hematology and Medical Oncology
Ohio State University-Main Campus
2011–2014
Internal Medicine
University of Michigan
2008–2011
Doctor of Medicine
2004–2008

Research

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
New England Journal of Medicine · 2018 · 782 citations
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Journal of Clinical Oncology · 2017 · 431 citations
Hypertension and incident cardiovascular events following ibrutinib initiation
Blood · 2019 · 219 citations

Jennifer Woyach
66 papers
JB
John Byrd
59 papers
Seema Bhat
49 papers
MG
Michael Grever
35 papers
Adam Kittai
27 papers · 1 as a fellow
Gerard Lozanski
24 papers
James Blachly
23 papers
LA
Leslie Andritsos
21 papers
Farrukh Awan
20 papers
Sameer Parikh
14 papers
JJ
Jeffrey Jones
13 papers
Kami Maddocks
13 papers

Grants

Targeted Therapies for Lymphoid Malignancies
National Cancer Institute · R01
PI · $2.6M · Ohio State University
2013–2026

Clinical trials

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Principal investigator · Recruiting · Phase 2
Kerry Rogers
2026–2027
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Principal investigator · Recruiting · Phase 2
Kerry Rogers
2024–2026
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Principal investigator · Recruiting · Phase 2
Ohio State University Comprehensive Cancer Center
2022–2026
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Principal investigator · Withdrawn · Phase 2
Kerry Rogers
2020–2021